Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.